GlassScriptPhysician profile
Julie Nguyen
NPI 1548581564
$5,525.76
in general payments reported to CMS, 2019-2025
30 companies · $2,866 in 2025
The $2,866 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $39.61 · 2021: $19.23 · 2023: $173 · 2024: $1,780 · 2025: $2,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,602 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,602.12 |
| Education | $216.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $782.81 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $607.93 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $425.14 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $424.57 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $359.40 | 2019-2025 | |
| Genzyme Corporation | $290.59 | 2019-2025 | |
| Incyte Corporation | $284.48 | 2024-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $279.07 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $270.48 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Allergan, INC. | $227.31 | 2019 | |
| Galderma Laboratories, L.P. | $199.17 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $198.06 | 2024-2025 | |
| Amgen INC. | $148.94 | 2024-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $145.00 | 2023 | Vtama |
| Inspire Medical Systems, INC. | $131.15 | 2024 | Inspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $105.85 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $100.34 | 2024-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.89 | 2024 | Siliq, Cabtreo |
| Leo Pharma INC. | $76.12 | 2024-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $72.78 | 2024-2025 | |
| Revance Therapeutics, INC. | $58.25 | 2024-2025 | Daxxify |
| Organon LLC | $38.24 | 2025 | |
| Celgene Corporation | $22.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.02 | 2024 | Spevigo |
| Jazz Pharmaceuticals INC. | $19.23 | 2021 | |
| Journey Medical Corporation | $17.99 | 2024 | |
| Botanix Sb INC | $17.18 | 2025 | Sofdra |
| Almirall LLC | $13.47 | 2019 | |
| Merck Sharp & Dohme LLC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.